Evidence map›Paper›PMID 37076693›Full record

ReviewLeukemia2023

Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group.

William Shomali, Philomena Colucci, Tracy I George, Jean-Jacques Kiladjian, Cheryl Langford, Jay L Patel, Andreas Reiter, Alessandro M Vannucchi, Jason Gotlib

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. [Guideline of the diagnosis and treatment of eosinophilic disorders (2024)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024
    Guideline
  2. Review
  3. Review
  4. Case reports in hematology · 2026
    Article
  5. Case reports in hematology · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

William ShomaliDivision of Hematology, Stanford Cancer Institute/Stanford University School of Medicine, Stanford, CA, USA.
Philomena ColucciIncyte Corporation, Wilmington, DE, USA.
Tracy I GeorgeARUP Laboratories and University of Utah School of Medicine, Salt Lake City, UT, USA.ORCID 0000-0001-5478-7847
Jean-Jacques KiladjianHôpital Saint-Louis, Paris, France.
Cheryl LangfordDivision of Hematology, Stanford Cancer Institute/Stanford University School of Medicine, Stanford, CA, USA.
Jay L PatelARUP Laboratories and University of Utah School of Medicine, Salt Lake City, UT, USA.
Andreas ReiterUniversitätsmedizin Mannheim, Mannheim, Germany.ORCID 0000-0002-7718-6507
Alessandro M VannucchiUniversity of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Jason GotlibDivision of Hematology, Stanford Cancer Institute/Stanford University School of Medicine, Stanford, CA, USA. Jason.gotlib@stanford.edu.ORCID 0000-0001-8253-6156

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

EosinophiliaLymphomaMyeloproliferative DisordersGene FusionHumansOncogene Proteins, FusionProtein-Tyrosine KinasesOncogene Proteins, FusionProtein-Tyrosine Kinases

Identifiers

PMID37076693
PMCPMC10169632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.